Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $274.48M |
| Gross Profit (TTM) | $228.26M |
| EBITDA | $134.45M |
| Operating Margin | 33.60% |
| Return on Equity | 17.10% |
| Return on Assets | 5.19% |
| Revenue/Share (TTM) | $14.07 |
| Book Value | $49.79 |
| Price-to-Book | 4.61 |
| Price-to-Sales (TTM) | 16.74 |
| EV/Revenue | 15.51 |
| EV/EBITDA | 19.03 |
| Quarterly Earnings Growth (YoY) | 103.20% |
| Quarterly Revenue Growth (YoY) | 14.10% |
| Shares Outstanding | $20.04M |
| Float | $19.57M |
| % Insiders | 2.39% |
| % Institutions | 106.34% |
Volatility is currently contracting